Tafinlar is a biological therapy that causes cancer cells with the BRAF V600 mutation to die which can delay or stop cancer growth. Apart from this drug, NICE has previously recommended vemurafenib and ipilimumab as therapies for this skin cancer type, Prof. Carole Longson, director of NICE centre for health technology evaluation, noted.
NICE commented that findings filed by GlaxoSmithKline indicated that dabrafenib works just as well as vemurafenib which also treats melanoma with the BRAF V600 mutation. In addition, agents like dabrafenib are believed to provide very fast positive effects for patients, even in people who are very unwell or bed-ridden. Moreover, in some cases, it has enabled people to resume everyday activities.
Furthermore, the institute recommends dabrafenib only if the firm provides the drug to the NHS with a discount on the list price.
Perrigo to acquire United States rights for Entocort from AstraZeneca
US FDA approves Boehringer Ingelheim's Pradaxa
Phase II clinical trial for potential treatment of androgenetic alopecia completed by Samumed
Life Sciences Partners collaborates on immuno-oncology with Bristol-Myers Squibb
Arsanis initiates first cohort in Phase one clinical trial of ASN100
Impax introduces generic Avodart (Dutasteride) Capsules, 0.5 mg
Mylan unveils generic FazaClo orally disintegrating tablets for treating schizophrenia